Identification

Name
Clindamycin
Accession Number
DB01190  (APRD00566)
Type
Small Molecule
Groups
Approved, Vet approved
Description

Clindamycin is a semisynthetic lincosamide antibiotic that has largely replaced lincomycin due to an improved side effect profile. Clindamycin inhibits bacterial protein synthesis by binding to bacterial 50S ribosomal subunits. It may be bacteriostatic or bactericidal depending on the organism and drug concentration.

Structure
Thumb
Synonyms
  • 7-CDL
  • 7(S)-Chloro-7-deoxylincomycin
  • Cleocin (tn)
  • Clindamicina
  • Clindamycin
  • Clindamycine
  • Clindamycinum
  • Methyl 7-chloro-6,7,8-trideoxy-6-(1-methyl-trans-4-propyl-L-2-pyrrolidinecarboxamido)-1-thio-L-threo-alpha-D-galacto-octopyranoside
External IDs
U-21,251 / U-21251
Product Ingredients
IngredientUNIICASInChI Key
Clindamycin hydrochlorideT20OQ1YN1W21462-39-5AUODDLQVRAJAJM-XJQDNNTCSA-N
Clindamycin palmitate hydrochlorideVN9A8JM7M725507-04-4GTNDZRUWKHDICY-DJHAJVGHSA-N
Clindamycin phosphateEH6D7113I824729-96-2UFUVLHLTWXBHGZ-KUWMELJBSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
CleocinCream20 mg/1gVaginalPhysicians Total Care, Inc.1992-08-112010-06-30Us
CleocinSuppository100 mg/1VaginalPhysicians Total Care, Inc.2003-12-302013-06-30Us
CleocinCream20 mg/1gVaginalPharmacia and Upjohn Company LLC1992-08-11Not applicableUs
CleocinSuppository100 mg/1VaginalPharmacia and Upjohn Company LLC1999-08-13Not applicableUs
CleocinSuppository100 mg/1VaginalU.S. Pharmaceuticals1999-08-13Not applicableUs
Cleocin HydrochlorideCapsule300 mg/1OralPharmacia and Upjohn Company LLC1970-05-22Not applicableUs
Cleocin HydrochlorideCapsule75 mg/1OralPharmacia and Upjohn Company LLC1970-05-22Not applicableUs00009 0331 02 nlmimage10 070803d0
Cleocin HydrochlorideCapsule150 mg/1OralPharmacia and Upjohn Company LLC1970-05-22Not applicableUs
Cleocin PhosphateInjection, solution150 mg/1mLIntramuscular; IntravenousPharmacia & Upjohn Inc2014-04-10Not applicableUs
Cleocin PhosphateInjection, solution150 mg/1mLIntramuscular; IntravenousPharmacia and Upjohn Company LLC1972-10-02Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-clindamycinCapsule300 mgOralApotex Corporation2002-02-20Not applicableCanada
Apo-clindamycinCapsule150 mgOralApotex Corporation2002-02-20Not applicableCanada
Auro-clindamycinCapsule300 mgOralAuro Pharma Inc2015-03-02Not applicableCanada
Auro-clindamycinCapsule150 mgOralAuro Pharma Inc2015-03-02Not applicableCanada
Ava-clindamycinCapsule150 mgOralAvanstra Inc2011-08-222014-08-21Canada
Ava-clindamycinCapsule300 mgOralAvanstra Inc2011-08-222014-08-21Canada
CleocinGranule, for solution75 mg/5mLOralPhysicians Total Care, Inc.2007-11-28Not applicableUs
Cleocin PediatricGranule, for solution75 mg/5mLOralPharmacia and Upjohn Company LLC1986-04-17Not applicableUs
Cleocin PhosphateInjection, solution150 mg/1mLIntravenousPharmacia and Upjohn Company LLC1987-10-16Not applicableUs
Cleocin PhosphateInjection, solution150 mg/1mLIntravenousPharmacia and Upjohn Company LLC1987-10-16Not applicableUs
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
AcanyaClindamycin phosphate (10 mg/1g) + Benzoyl peroxide (25 mg/1g)GelTopicalValent Pharmaceuticals North America2010-07-26Not applicableUs
AcanyaClindamycin phosphate (10 mg/1mL) + Benzoyl peroxide (25 mg/1g)KitDow Pharmaceuticals Sciences2009-02-032014-04-30Us
BenzaclinClindamycin phosphate (10 mg/1g) + Benzoyl peroxide (50 mg/1g)GelTopicalValeant Pharmaceuticals North America2000-12-21Not applicableUs
BenzaclinClindamycin phosphate (10 mg/1g) + Benzoyl peroxide (50 mg/1g)GelTopicalPhysicians Total Care, Inc.2009-08-27Not applicableUs
BenzaclinClindamycin phosphate (10 mg/1g) + Benzoyl peroxide (50 mg/1g)GelTopicalDermik Laboratories2000-12-212013-12-31Us
Benzaclin Topical GelClindamycin (1 %) + Benzoyl peroxide (5 %)GelTopicalValeant Canada Lp Valeant Canada S.E.C.2004-05-04Not applicableCanada
Biacna Topical GelClindamycin phosphate (1.200 %) + Tretinoin (0.025 %)GelTopicalValeant Canada Lp Valeant Canada S.E.C.2011-05-16Not applicableCanada
CLIN-LIDO-Single Use KitClindamycin phosphate (150 mg/1mL) + Epinephrine (10 ug/1mL) + Lidocaine hydrochloride (10 mg/1mL) + Sodium bicarbonate (84 mg/1mL)KitInfiltration; Intramuscular; IntravenousBurke Therapeutics, LLC2015-06-182015-09-11Us
Clindamycin - Benzoyl PeroxideClindamycin phosphate (10 mg/1g) + Benzoyl peroxide (50 mg/1g)GelTopicalPrasco Laboratories2012-06-27Not applicableUs
Clindamycin and Benzoyl PeroxideClindamycin phosphate (10 mg/1g) + Benzoyl peroxide (50 mg/1g)KitTopicalSandoz2017-08-15Not applicableUs
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Clindap-TClindamycin phosphate (0.5 g/0.5g) + Adapalene (0.15 g/0.15g)KitAccumix Pharmaceuticals2014-12-152015-07-17Us
International/Other Brands
Clinimycin (Hayat) / Dalacin C (Pfizer) / Dalacin T Topical Solution (Pfizer) / Zindaclin (Crawford)
Categories
UNII
3U02EL437C
CAS number
18323-44-9
Weight
Average: 424.983
Monoisotopic: 424.179870573
Chemical Formula
C18H33ClN2O5S
InChI Key
KDLRVYVGXIQJDK-AWPVFWJPSA-N
InChI
InChI=1S/C18H33ClN2O5S/c1-5-6-10-7-11(21(3)8-10)17(25)20-12(9(2)19)16-14(23)13(22)15(24)18(26-16)27-4/h9-16,18,22-24H,5-8H2,1-4H3,(H,20,25)/t9-,10+,11-,12+,13-,14+,15+,16+,18+/m0/s1
IUPAC Name
(2S,4R)-N-[(1S,2S)-2-chloro-1-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(methylsulfanyl)oxan-2-yl]propyl]-1-methyl-4-propylpyrrolidine-2-carboximidic acid
SMILES
[H][C@@](C)(Cl)[C@@]([H])(N=C(O)[C@]1([H])C[C@@]([H])(CCC)CN1C)[C@@]1([H])O[C@]([H])(SC)[C@]([H])(O)[C@@]([H])(O)[C@@]1([H])O

Pharmacology

Indication

For the treatment of serious infections caused by susceptible anaerobic bacteria, including Bacteroides spp., Peptostreptococcus, anaerobic streptococci, Clostridium spp., and microaerophilic streptococci. May be useful in polymicrobic infections such as intra-abdominal or pelvic infections, osteomyelitis, diabetic foot ulcers, aspiration pneumonia and dental infections. May also be used to treat MSSA and respiratory infections caused by S. pneumoniae and S. pyogenes in patients who are intolerant to other indicated antibiotics or who are infected with resistant organism. May be used vaginally to treat vaginosis caused by Gardnerella vaginosa. Clindamycin reduces the toxin producing effects of S. aureus and S. pyogenes and as such, may be particularly useful for treating necrotizing fasciitis. May be used topically to treat acne.

Associated Conditions
Associated Therapies
Pharmacodynamics

Clindamycin is an antibiotic, similar to and a derivative of lincomycin. Clindamycin can be used in topical or systemic treatment. It is effective as an anti-anaerobic antibiotic and antiprotozoal.

Mechanism of action

Systemic/vaginal clindamycin inhibits protein synthesis of bacteria by binding to the 50S ribosomal subunits of the bacteria. Specifically, it binds primarily to the 23s RNA subunit. Topical clindamycin reduces free fatty acid concentrations on the skin and suppresses the growth of Propionibacterium acnes (Corynebacterium acnes) , an anaerobe found in sebaceous glands and follicles.

TargetActionsOrganism
A50S ribosomal protein L10
inhibitor
Shigella flexneri
A23S rRNA
inhibitor
Enteric bacteria and other eubacteria
Absorption

Rapidly absorbed after oral administration with peak serum concentrations observed after about 45 minutes. Absorption of an oral dose is virtually complete (90%) and the concomitant intake of food does not appreciably modify the serum concentrations; serum levels have been uniform and predictable from person to person and dose to dose. Clindamycin does not penetrate the blood brain barrier.

Volume of distribution
Not Available
Protein binding

92-94%

Metabolism

Hepatic

Route of elimination

Approximately 10% of the bioactivity is excreted in the urine and 3.6% in the feces; the remainder is excreted as bioinactive metabolites.

Half life

2.4 hours

Clearance
Not Available
Toxicity

Adverse effects include nausea (may be dose-limiting), diarrhea, pseudomembranous colitis, allergic reactions, hepatoxicity, transient neutropenia and eosinophilia and agranulocytosis. Pseudomembranous colitis occurs in 0.01 - 10% of patients and occurs more commonly than with other antibiotics. Use of the topical formulation of clindamycin results in absorption of the antibiotic from the skin surface. Diarrhea, bloody diarrhea, and colitis (including pseudomembranous colitis) have been reported with the use of topical and systemic clindamycin.

Affected organisms
  • Enteric bacteria and other eubacteria
Pathways
PathwayCategory
Clindamycin Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
2,5-Dimethoxy-4-ethylamphetamineClindamycin may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.
2,5-Dimethoxy-4-ethylthioamphetamineClindamycin may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.
3,4-MethylenedioxyamphetamineThe risk or severity of adverse effects can be increased when 3,4-Methylenedioxyamphetamine is combined with Clindamycin.
4-Bromo-2,5-dimethoxyamphetamineClindamycin may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.
4-MethoxyamphetamineThe risk or severity of adverse effects can be increased when 4-Methoxyamphetamine is combined with Clindamycin.
5-methoxy-N,N-dimethyltryptamineThe risk or severity of adverse effects can be increased when Clindamycin is combined with 5-methoxy-N,N-dimethyltryptamine.
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Clindamycin.
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineThe risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Clindamycin.
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Clindamycin.
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Clindamycin.
Food Interactions
  • Take with food.

References

Synthesis Reference

Donald E. Ayer, Carl A. Schlagel, Gordon L. Flynn, "Topical clindamycin preparations." U.S. Patent US4018918, issued January, 1971.

US4018918
General References
  1. Daum RS: Clinical practice. Skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus. N Engl J Med. 2007 Jul 26;357(4):380-90. [PubMed:17652653]
  2. Klempner MS, Styrt B: Clindamycin uptake by human neutrophils. J Infect Dis. 1981 Nov;144(5):472-9. [PubMed:6171600]
  3. Lamont RF: Can antibiotics prevent preterm birth--the pro and con debate. BJOG. 2005 Mar;112 Suppl 1:67-73. [PubMed:15715599]
  4. Plaisance KI, Drusano GL, Forrest A, Townsend RJ, Standiford HC: Pharmacokinetic evaluation of two dosage regimens of clindamycin phosphate. Antimicrob Agents Chemother. 1989 May;33(5):618-20. [PubMed:2751277]
External Links
KEGG Drug
D00277
KEGG Compound
C06914
PubChem Compound
446598
PubChem Substance
46506073
ChemSpider
393915
ChEBI
3745
ChEMBL
CHEMBL1753
Therapeutic Targets Database
DAP000409
PharmGKB
PA449035
HET
CLY
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Clindamycin
ATC Codes
J01FF01 — ClindamycinG01AA10 — ClindamycinD10AF51 — Clindamycin, combinationsD10AF01 — Clindamycin
AHFS Codes
  • 84:04.04 — Antibiotics
  • 08:12.28.20 — Lincomycins
PDB Entries
1jzx / 1yjn / 3jz0 / 4v7v
FDA label
Download (151 KB)
MSDS
Download (72.8 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedTreatmentVaginal Inflammation1
0RecruitingTreatmentOsteomyelitis1
1Active Not RecruitingOtherBacterial Infections1
1CompletedNot AvailableAcne Vulgaris1
1CompletedNot AvailableHealthy Volunteers2
1CompletedBasic ScienceBacterial Infections / BMI >30 kg/m21
1CompletedTreatmentAcne Vulgaris4
1, 2CompletedTreatmentAcne Vulgaris1
2CompletedPreventionSurgical Site Infections1
2CompletedTreatmentAcne Vulgaris1
2CompletedTreatmentInfection caused by staphylococci1
2CompletedTreatmentRash1
2Not Yet RecruitingTreatmentAbdominal Abscess1
2RecruitingTreatmentBacterial Vaginosis Treatment1
2RecruitingTreatmentColorectal Cancers / Head and Neck Carcinoma1
2RecruitingTreatmentPre-Diabetic1
2TerminatedTreatmentOsteomyelitis1
2Unknown StatusTreatmentHip Prosthetic Joint Infection1
2Unknown StatusTreatmentPlasmodium Infections1
2, 3CompletedTreatmentComplicated Intra Abdominal Infections1
2, 3CompletedTreatmentInfection caused by staphylococci1
2, 3CompletedTreatmentRosaceas1
2, 3Not Yet RecruitingTreatmentSymptomatic Periapical Periodontitis1
3CompletedTreatmentAcne2
3CompletedTreatmentAcne Vulgaris9
3CompletedTreatmentAcne / Acne Vulgaris1
3CompletedTreatmentBacterial Vaginosis (BV)1
3CompletedTreatmentDiabetes Mellitus (DM) / Periodontal Pocket / Periodontitis1
3CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Pneumonia, Pneumocystis Carinii1
3CompletedTreatmentPlasmodium Infections2
3CompletedTreatmentSkin Diseases, Bacterial / Skin Diseases, Infectious1
3CompletedTreatmentVaginal Inflammation / Vulvovaginitis1
3RecruitingOtherRenal Stones1
3RecruitingPreventionAtrioventricular block complete / Chronic Systolic Heart Failure / Sick Sinus Syndrome / Syncope1
3RecruitingTreatmentAcne Vulgaris2
3RecruitingTreatmentStaphylococcus Aureus Infections1
3Unknown StatusTreatmentBacterial Vaginosis (BV) / Candidiasis infection1
3Unknown StatusTreatmentDiffuse posterior uveitis1
3WithdrawnTreatmentInfection NOS / Skin Diseases1
4Active Not RecruitingTreatmentCellulitis1
4CompletedNot AvailableBacterial Endophthalmitis / Endophthalmitis / Prophylaxy of Post Traumatic Endophthalmitis1
4CompletedNot AvailablePerforated Appendicitis1
4CompletedPreventionBacterial Vaginosis (BV) / Pregnancy / Premature Babies / Premature Births1
4CompletedPreventionEmpyema / Pleural Effusions / Pleuritis1
4CompletedPreventionPregnancy1
4CompletedTreatmentAbscesses / Folliculitis / Infection caused by staphylococci / Staphylococcal Skin Infections1
4CompletedTreatmentAcne1
4CompletedTreatmentAcne Vulgaris12
4CompletedTreatmentAcne Vulgaris / Post Inflammatory Hyperpigmentation1
4CompletedTreatmentAnti-Infective Agents / Bacterial Infections / Breast Implantation1
4CompletedTreatmentFocal Infection, Dental1
4RecruitingPreventionFractures, Open / Post-Op Wound Infection1
4RecruitingPreventionPost Operative Wound Infection / Supracondylar Humerus Fractures1
4RecruitingTreatmentBacterial Vaginosis (BV)1
4RecruitingTreatmentBacterial Vaginosis (BV) / Candidiasis infection1
4RecruitingTreatmentSeptic Abortion1
4Unknown StatusTreatmentAcne1
4Unknown StatusTreatmentAcne Vulgaris1
4Unknown StatusTreatmentAmputation Wound / Wound Infections1
4WithdrawnPreventionComplications; Breast Prosthesis, Infection or Inflammation1
4WithdrawnTreatmentPneumonia, Pneumocystis Carinii1
Not AvailableCompletedTreatmentAbscesses / Skin Diseases, Bacterial1
Not AvailableCompletedTreatmentAcne Vulgaris1
Not AvailableCompletedTreatmentCervical Insufficiency1
Not AvailableCompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Pneumonia, Pneumocystis Carinii1
Not AvailableCompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Toxoplasmosis, Cerebral2
Not AvailableCompletedTreatmentMild to severe acne vulgaris1
Not AvailableEnrolling by InvitationTreatmentPartially Edentulous Jaw1
Not AvailableNot Yet RecruitingPreventionCutaneous lesions1
Not AvailableRecruitingNot AvailableGeneral Surgery1
Not AvailableRecruitingNot AvailableInfertility, Female1
Not AvailableRecruitingPreventionForeskin HIV Susceptibility1
Not AvailableRecruitingPreventionMotility Disorders / Staphylococcus Aureus1
Not AvailableRecruitingTreatmentAbnormal Vaginal Flora / Clindamycin Vs Metronidazole / High Risk Pregnancies for Preterm Labor1
Not AvailableRecruitingTreatmentAnal Fistulas1
Not AvailableRecruitingTreatmentInfection caused by staphylococci1
Not AvailableRecruitingTreatmentProsthetic Joint Infection1
Not AvailableTerminatedTreatmentAbscess Soft Tissue / Methicillin-resistant Staphylococcus Aureus (MRSA) Infection / Skin Abscess1
Not AvailableTerminatedTreatmentSimple Hand Lacerations1
Not AvailableUnknown StatusPreventionBisphosphonate-Associated Osteonecrosis of the Jaw1
Not AvailableUnknown StatusPreventionDentofacial Deformity1
Not AvailableUnknown StatusTreatmentEndometritis1
Not AvailableUnknown StatusTreatmentHidradenitis Suppurativa (HS)1
Not AvailableWithdrawnTreatmentPeritonsillar Abscess1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
  • Accra Pac Inc.
  • Aidarex Pharmacuticals LLC
  • Ameri-Pac Inc.
  • Amerisource Health Services Corp.
  • Apotheca Inc.
  • APP Pharmaceuticals
  • A-S Medication Solutions LLC
  • Aurobindo Pharma Ltd.
  • Baxter International Inc.
  • Bedford Labs
  • Ben Venue Laboratories Inc.
  • Bryant Ranch Prepack
  • Cardinal Health
  • Catalent Pharma Solutions
  • Contract Pharm
  • Corepharma LLC
  • Coria Laboratories
  • Coupler Enterprises Inc.
  • Dermik Labs
  • Direct Dispensing Inc.
  • Dispensing Solutions
  • Diversified Healthcare Services Inc.
  • Dow Pharmaceutical Sciences
  • DPT Laboratories Ltd.
  • E. Fougera and Co.
  • Galderma Laboratories
  • Gallipot
  • Greenstone LLC
  • H.J. Harkins Co. Inc.
  • Heartland Repack Services LLC
  • Hospira Inc.
  • Innoviant Pharmacy Inc.
  • Inyx Usa Ltd.
  • Kaiser Foundation Hospital
  • Keltman Pharmaceuticals Inc.
  • Kleen Test Products Corp.
  • KV Pharmaceutical Co.
  • Lake Erie Medical and Surgical Supply
  • Lannett Co. Inc.
  • Liberty Pharmaceuticals
  • Major Pharmaceuticals
  • Mckesson Corp.
  • Medisca Inc.
  • Murfreesboro Pharmaceutical Nursing Supply
  • Mylan
  • Novopharm Ltd.
  • Nucare Pharmaceuticals Inc.
  • Nycomed Inc.
  • Ohm Laboratories Inc.
  • Paddock Labs
  • Palmetto Pharmaceuticals Inc.
  • Patheon Inc.
  • PCA LLC
  • PD-Rx Pharmaceuticals Inc.
  • Perrigo Co.
  • Pfizer Inc.
  • Pharmaceutical Utilization Management Program VA Inc.
  • Pharmacia Inc.
  • Pharmaderm
  • Pharmedix
  • Physician Partners Ltd.
  • Physicians Total Care Inc.
  • Preferred Pharmaceuticals Inc.
  • Prepackage Specialists
  • Prepak Systems Inc.
  • Quality Care
  • Ranbaxy Laboratories
  • Rebel Distributors Corp.
  • Redpharm Drug
  • Remedy Repack
  • Resource Optimization and Innovation LLC
  • Sandoz
  • Sanofi-Aventis Inc.
  • Sirius Labs
  • Southwood Pharmaceuticals
  • Spectrum Pharmaceuticals
  • St Mary's Medical Park Pharmacy
  • Stat Rx Usa
  • Stiefel Labs
  • Taro Pharmaceuticals USA
  • Teva Pharmaceutical Industries Ltd.
  • Ther-Rx Corp.
  • Tya Pharmaceuticals
  • UDL Laboratories
  • Unimed Pharmaceuticals Inc.
  • Watson Pharmaceuticals
  • Wockhardt Ltd.
Dosage forms
FormRouteStrength
Kit
GelTopical
Granule, for solutionOral75 mg/5mL
SuppositoryVaginal100 mg/1
Injection, solutionIntramuscular; Intravenous12 mg/1mL
Injection, solutionIntramuscular; Intravenous18 mg/1mL
Injection, solutionIntramuscular; Intravenous6 mg/1mL
KitInfiltration; Intramuscular; Intravenous
KitIntramuscular; Intravenous150 mg/1mL
Kit10 mg/1
SwabTopical10 mg/1
GelTopical1 g/10mL
GelTopical10 mg/1mL
CreamVaginal20 mg/1g
GelTopical10 mg/1g
SuspensionTopical10 mg/1mL
InjectionIntravenous150 mg/1mL
InjectionIntravenous300 mg/50mL
InjectionIntravenous600 mg/50mL
InjectionIntravenous900 mg/50mL
Injection, solution, concentrateIntramuscular; Intravenous150 mg/1mL
Injection, solution, concentrateIntravenous150 mg/1mL
KitTopical
CapsuleOral150 mg/1
CapsuleOral300 mg/1
CapsuleOral75 mg/1
Capsule, gelatin coatedOral150 mg/1
Capsule, gelatin coatedOral300 mg/1
Capsule, gelatin coatedOral75 mg/1
Injection, solutionIntravenous12 mg/1mL
Injection, solutionIntravenous18 mg/1mL
Injection, solutionIntravenous6 mg/1mL
LiquidIntramuscular; Intravenous150 mg
SolutionIntravenous150 mg
SolutionIntravenous12 mg
SolutionIntravenous18 mg
SolutionIntravenous6 mg
SolutionOral75 mg/5mL
Powder, for solutionOral75 mg/5mL
Injection, solutionIntramuscular; Intravenous150 mg/1mL
Injection, solutionIntravenous150 mg/1mL
Injection, solutionIntravenous300 mg/50mL
Injection, solutionIntravenous600 mg/50mL
Injection, solutionIntravenous900 mg/50mL
LotionTopical10 mg/1mL
SolutionTopical10 mg/1mL
SolutionTopical11.9 mg/1mL
CreamTopical
CreamVaginal100 mg/5g
SwabTopical1 %
Powder, for solutionOral75 mg
SolutionIntramuscular; Intravenous150 mg
SolutionTopical1 %
CreamVaginal20 mg
Aerosol, foamTopical10 mg/1g
CapsuleOral150 mg
CapsuleOral300 mg
Prices
Unit descriptionCostUnit
Clindagel 1% Gel 75ml Bottle324.48USD bottle
Evoclin 1% Foam 100 gm Can306.79USD can
Clindamycin Phosphate 1% Foam 100 gm Can286.04USD can
Evoclin 1% Foam 50 gm Can207.67USD can
Clindagel 1% Gel 40ml Bottle203.42USD bottle
Clindamycin Phosphate 1% Foam 50 gm Can186.9USD can
Clindamycin Phos-Benzoyl Perox 1-5% Gel 50 gm Jar176.42USD jar
Cleocin-T 1% Gel 60 gm Tube112.84USD tube
Cleocin-T 1% Lotion 60ml Bottle86.09USD bottle
Cleocin-T 60 1% Swab Box82.6USD box
Cleocin 2% Cream 40 gm Tube81.56USD tube
Cleocin 3 100 mg Suppository Box80.05USD box
Cleocin 75 mg/5ml Solution 100ml Bottle78.7USD bottle
Clindamycin hcl crystals74.9USD g
Clindamycin Phosphate 1% Gel 60 gm Tube71.42USD tube
Cleocin-T 1% Solution 60ml Bottle69.29USD bottle
Cleocin-T 1% Gel 30 gm Tube62.98USD tube
Clindamycin Phosphate 2% Cream 40 gm Tube54.99USD tube
Clindamycin Phosphate 60 1% Swab Box47.74USD box
Clindamycin Phosphate 1% Lotion 60ml Bottle46.92USD bottle
Clindesse 2% vaginal cream39.08USD g
Clindamycin Phosphate 1% Gel 30 gm Tube33.41USD tube
Clindamycin Phosphate 1% Solution 60ml Bottle24.07USD bottle
Clindamycin phosphate powdr21.42USD g
Clindamycin Phosphate 1% Solution 30ml Bottle14.99USD bottle
Cleocin hcl 300 mg capsule9.11USD capsule
Clindamycin phos crystals7.73USD g
Evoclin 1% foam4.9USD g
Clindagel 1% gel4.89USD ml
Cleocin 150 mg capsule4.66USD capsule
Dalacin C Phosphate 150 mg/ml4.53USD ml
Clindamycin hcl 300 mg capsule3.98USD capsule
Clindamycin phosphate 1% foam3.59USD g
Clindamycin 150 mg/ml3.48USD ml
Clindamycin (60 & 120 Ml) 150 mg/ml3.41USD ml
Cleocin hcl 150 mg capsule2.79USD capsule
Cleocin hcl 75 mg capsule2.28USD capsule
Dalacin C 300 mg Capsule2.12USD capsule
Cleocin 2% vaginal cream1.97USD g
Clindamycin 150 mg/ml addvan1.97USD ml
Cleocin phos 150 mg/ml vial1.91USD ml
Cleocin t 1% gel1.81USD g
Clindamycin ph 300 mg/2 ml vial1.74USD ml
Clindamax 2% vaginal cream1.37USD g
Clindamycin 2% vaginal cream1.27USD g
Clindamycin hcl 150 mg capsule1.21USD capsule
Clindets 1% pledgets1.1USD each
Dalacin C 150 mg Capsule1.06USD capsule
Apo-Clindamycin 300 mg Capsule1.02USD capsule
Mylan-Clindamycin 300 mg Capsule1.02USD capsule
Novo-Clindamycin 300 mg Capsule1.02USD capsule
Clindamycin ph 9 g/60 ml vial0.93USD ml
Apo-Clindamycin 150 mg Capsule0.51USD capsule
Mylan-Clindamycin 150 mg Capsule0.51USD capsule
Novo-Clindamycin 150 mg Capsule0.51USD capsule
Clinda-derm 1% solution0.4USD ml
Cleocin 900 mg-d5w-galaxy0.37USD ml
Cleocin 600 mg-d5w-galaxy0.3USD ml
Dalacin C Palmitate 15 mg/ml Solution0.14USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5266329No1993-11-302010-11-30Us
US5993856No1997-11-172017-11-17Us
US6387383No2000-08-032020-08-03Us
US7374747No2006-08-092026-08-09Us
US7141237No2004-01-232024-01-23Us
US8288434No2009-08-052029-08-05Us
US8663699No2009-06-032029-06-03Us
US8895070No2009-06-032029-06-03Us
US9078870No2009-06-032029-06-03Us
US6495157No2000-07-202020-07-20Us
US6899890No2003-04-272023-04-27Us
US9504704No2009-06-032029-06-03Us
US9561208No2009-06-032029-06-03Us
US9789057No2006-12-022026-12-02Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)142 [HCl salt]Not Available
water solubility30.6 mg/LNot Available
logP2.16HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.46 mg/mLALOGPS
logP1.59ALOGPS
logP1.09ChemAxon
logS-3ALOGPS
pKa (Strongest Acidic)5.91ChemAxon
pKa (Strongest Basic)6.74ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area105.75 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity106.24 m3·mol-1ChemAxon
Polarizability44.99 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.8143
Blood Brain Barrier-0.9697
Caco-2 permeable-0.8236
P-glycoprotein substrateSubstrate0.7653
P-glycoprotein inhibitor INon-inhibitor0.7311
P-glycoprotein inhibitor IIInhibitor0.7894
Renal organic cation transporterNon-inhibitor0.8784
CYP450 2C9 substrateNon-substrate0.8214
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.6762
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8876
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9107
Ames testNon AMES toxic0.6967
CarcinogenicityNon-carcinogens0.9172
BiodegradationNot ready biodegradable0.994
Rat acute toxicity2.3192 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9887
hERG inhibition (predictor II)Non-inhibitor0.59
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as proline and derivatives. These are compounds containing proline or a derivative thereof resulting from reaction of proline at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Proline and derivatives
Alternative Parents
Alpha amino acid amides / Thioglycosides / Pyrrolidinecarboxamides / Monosaccharides / N-alkylpyrrolidines / Oxanes / Monothioacetals / Trialkylamines / Secondary carboxylic acid amides / Secondary alcohols
show 10 more
Substituents
Proline or derivatives / Alpha-amino acid amide / Glycosyl compound / S-glycosyl compound / Pyrrolidine carboxylic acid or derivatives / Pyrrolidine-2-carboxamide / Monosaccharide / Oxane / N-alkylpyrrolidine / Monothioacetal
show 27 more
Molecular Framework
Aliphatic heteromonocyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Shigella flexneri
Pharmacological action
Yes
Actions
Inhibitor
General Function
Structural constituent of ribosome
Specific Function
Protein L10 is also a translational repressor protein. It controls the translation of the rplJL-rpoBC operon by binding to its mRNA (By similarity).Forms part of the ribosomal stalk, playing a cent...
Gene Name
rplJ
Uniprot ID
P0A7J6
Uniprot Name
50S ribosomal protein L10
Molecular Weight
17711.38 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Schlunzen F, Zarivach R, Harms J, Bashan A, Tocilj A, Albrecht R, Yonath A, Franceschi F: Structural basis for the interaction of antibiotics with the peptidyl transferase centre in eubacteria. Nature. 2001 Oct 25;413(6858):814-21. [PubMed:11677599]
2. 23S rRNA
Kind
Nucleotide
Organism
Enteric bacteria and other eubacteria
Pharmacological action
Yes
Actions
Inhibitor
References
  1. Schlunzen F, Zarivach R, Harms J, Bashan A, Tocilj A, Albrecht R, Yonath A, Franceschi F: Structural basis for the interaction of antibiotics with the peptidyl transferase centre in eubacteria. Nature. 2001 Oct 25;413(6858):814-21. [PubMed:11677599]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Wynalda MA, Hutzler JM, Koets MD, Podoll T, Wienkers LC: In vitro metabolism of clindamycin in human liver and intestinal microsomes. Drug Metab Dispos. 2003 Jul;31(7):878-87. doi: 10.1124/dmd.31.7.878. [PubMed:12814964]

Drug created on June 13, 2005 07:24 / Updated on October 16, 2018 08:35